MDCG 2026-5 UDI Assignment: Manufacturer vs Distributor Decision Tree
MDCG 2026-5 UDI assignment guide: 3-path decision tree for private-label distributor brands, MDR Article 16, Basic UDI-DI rules, and EUDAMED registration.
In European medical device distribution, private-label and own-brand arrangements are common commercial structures. A medical device manufacturer develops and CE-marks a device, but a distributor markets and sells the device across hospitals and retail channels under its own distributor trade name or house brand. For years, commercial teams frequently arranged for the distributor to obtain its own Unique Device Identifier (UDI-DI) from an issuing agency (such as GS1, HIBCC, ICCBBA, or IFA) under the distributor's corporate membership account.
In July 2026, the Medical Device Coordination Group endorsed MDCG 2026-5 (Position Paper: UDI assignment between manufacturers and distributors). The document addresses this widespread market practice and clarifies the division of responsibilities under Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR).
The Core Direct Answer: If the original manufacturer remains identified as the legal manufacturer on the device label, the distributor must not obtain a UDI-DI in its own name or from its own issuing-entity account. MDCG 2026-5 confirms that assigning two distinct UDI-DIs for two trade names is acceptable, but both UDI-DIs must be linked solely to the legal manufacturer in issuing-entity databases and in the EUDAMED UDI/Device module. Only the legal manufacturer indicated on the label may assign UDIs, receive codes from EU UDI issuing entities linked to itself, and register the device in EUDAMED.
Under MDR Article 16: When Importers and Distributors Become Manufacturers, if a distributor markets a device under its own brand without an Article 16(1)(a) exception agreement, the distributor assumes manufacturer obligations, must assign a new Basic UDI-DI, obtain a manufacturer Single Registration Number (SRN), and complete the applicable conformity-assessment procedure.
This guide provides an operational decision tree for manufacturers, distributors, and authorised representatives navigating MDCG 2026-5, breaks down the three Article 16 regulatory paths, explains EUDAMED record ownership, and outlines a 30/60/90-day operational cleanup sequence. It is not a statutory timetable: MDCG 2026-5 sets none.
Do not confuse this private-label UDI-account question with pack-level UDI for systems and procedure packs under Article 22.
What Does MDCG 2026-5 Actually Say About Distributor-Assigned UDI-DIs?
MDCG 2026-5 was endorsed by the Medical Device Coordination Group (established under MDR Article 103) in July 2026. The position paper examines a specific commercial scenario: a distributor wishes to make a device available under its own trade name or trademark, while an agreement under MDR Article 16(1)(a) ensures that the original manufacturer remains identified as such on the label and remains responsible for manufacturer requirements.
| Element | MDCG 2026-5 position |
|---|---|
| Original manufacturer named on the label | Remains the legal manufacturer under the Article 16(1)(a) agreement |
| Distributor brand / private-label trade name | May appear commercially; does not move UDI assignment |
| Second trade name | A second UDI-DI is appropriate |
| Who may request and hold that UDI-DI | Only the manufacturer named on the label |
| Issuing-entity account | Must be the manufacturer's; codes must be linked to the manufacturer |
| EUDAMED UDI/Device registrant | The manufacturer, under its manufacturer SRN |
The Commercial Practice Addressed
Historically, distributors marketing devices under private labels often purchased their own GS1 Global Trade Item Numbers (GTINs) or HIBCC Universal Product Numbers (UPNs) to control retail catalogues, enterprise resource planning (ERP) systems, and hospital supply contracts.
MDCG 2026-5 describes that practice as the problem: distributors obtain UDI-DI codes in their own name from EU UDI issuing entities, including under an Article 16(1)(a) agreement that keeps the original manufacturer on the label. Two different UDI-DIs for two trade names remain appropriate, but that assignment must be made solely by the manufacturer. Issuing entities should provide and link codes to the company acting as manufacturer.
Statutory Foundation
The position paper grounds this conclusion in core MDR and IVDR provisions:
- UDI specificity (MDR Article 27(1)(a)(i) / IVDR Article 24(1)(a)(i)): the UDI-DI is specific to a manufacturer and a device.
- Assignment obligation (MDR/IVDR Annex VI Part C 2.2): the manufacturer shall assign and maintain unique UDIs for its devices.
- Placement on the device (MDR/IVDR Annex VI Part C 2.3): only the manufacturer may place the UDI on the device or its packaging.
- General manufacturer obligations (MDR Article 10(7) / IVDR Article 10(6)): manufacturers shall comply with UDI-system and registration obligations (MDR Articles 27, 29 and 31; IVDR Articles 24, 26 and 28).
Legal Status and Regulatory Weight
Like other MDCG documents, MDCG 2026-5 states that it is not a European Commission document and is not legally binding. Binding interpretations of Union law are for the Court of Justice of the European Union (CJEU).
The paper's stated aim is still operationally important: it is written to support clarity, transparency and consistency across EU Member States in their enforcement of UDI provisions and the operation of EUDAMED. Competent authorities and notified bodies commonly use MDCG position papers when they interpret those provisions. That is not the same thing as an amendment of MDR or IVDR text.
Which Article 16 Path Are You On: Exception, New Manufacturer, or Relabel/Repack?
To determine UDI assignment and EUDAMED obligations, identify which branch of MDR Article 16 (or IVDR Article 16) actually governs the arrangement.
- Is the device made available under a distributor's name, registered trade name, or registered trademark?
- No — manufacturer-brand only. The manufacturer assigns UDI as usual. Article 16(1)(a) is not in play.
- Yes — go to step 2.
- Is there a valid Article 16(1)(a) agreement that keeps the original manufacturer identified as such on the label and responsible for manufacturer requirements?
- Yes — Pathway A (exception). Extra trade names get extra manufacturer-assigned UDI-DIs under the manufacturer's Basic UDI-DI.
- No — Pathway B. The distributor (or importer or other person) assumes manufacturer obligations, including UDI.
- Separately: is the economic operator only translating the IFU or changing outer packaging under Article 16(2)?
- Yes — Pathway C. UDI assignment stays with the original manufacturer. Article 16(3)–(4) QMS and notified-body certificate rules apply. This path is not a licence to hold the identifier.
Pathway A: Article 16(1)(a) Agreement Exception (Manufacturer on Label)
- Trigger: A distributor makes a device available under its own trade name or trademark, but has entered into an agreement whereby the original manufacturer remains identified as such on the label and remains responsible for meeting manufacturer requirements.
- UDI-DI assignment: The original manufacturer assigns any secondary UDI-DI required for the distributor's trade name, from the original manufacturer's issuing-entity account.
- Basic UDI-DI: The device retains the original manufacturer's Basic UDI-DI (MDCG 2022-7 Question 2).
- EUDAMED registration: The original manufacturer registers the device and associated trade names and UDI-DIs under its own manufacturer SRN.
- Distributor status: The distributor remains an Article 14 economic operator and does not become the legal manufacturer.
Pathway B: Article 16(1) Full Assumption of Manufacturer Obligations
- Trigger: A distributor, importer, or other person makes a device available under its own name, registered trade name, or registered trademark without an Article 16(1)(a) agreement (or where the original manufacturer is removed from the label).
- Legal transformation: Under Article 16(1), that person assumes the obligations incumbent on manufacturers, including UDI.
- Basic UDI-DI and UDI-DI: MDCG 2022-7 Question 2 says that person must assign a new Basic UDI-DI, register as a manufacturer, receive an SRN, apply for the appropriate conformity-assessment procedure, and provide UDI/device registration.
- EUDAMED registration: Device records sit under the new manufacturer's SRN, not the original manufacturer's.
A blanket slogan that "distributors never assign UDI" is false on this path. The person who has become the manufacturer does assign UDI — as manufacturer, not as distributor.
Pathway C: Article 16(2) Translation and Outer Packaging Changes
- Trigger: An importer or distributor translates information supplied with the device, or changes outer packaging (including pack size) as described in Article 16(2), in order to market the device in a Member State.
- UDI rules: Assignment stays with the original manufacturer. Relabelling or repackaging does not transfer UDI-DI or Basic UDI-DI ownership. The UDI Helpdesk states that those operations must not compromise readability of the UDI carrier.
- Operational duties: The economic operator must preserve the original condition of the device, operate a quality management system under Article 16(3), and meet Article 16(4): at least 28 days before making the relabelled or repackaged device available, inform the manufacturer and the competent authority of the Member State concerned; provide a sample or mock-up on request; and, within the same 28 days, submit to that competent authority a notified-body certificate that the QMS complies with Article 16(3). The 28-day notice is not a notice to the notified body.
Cross-Pathway Comparison Table
| Attribute | Pathway A: Article 16(1)(a) exception | Pathway B: Article 16(1) assumption | Pathway C: Article 16(2) relabel / repack |
|---|---|---|---|
| Entity named as manufacturer on the label | Original manufacturer | Distributor (now the manufacturer) | Original manufacturer |
| Legal status of the distributor | Distributor (Article 14) | Manufacturer (Article 10) | Relabeler / repackager (Article 16(2)) |
| Basic UDI-DI | Retain the original manufacturer's Basic UDI-DI | New Basic UDI-DI assigned by the new manufacturer | Original manufacturer's Basic UDI-DI |
| UDI-DI issuing-entity account | Original manufacturer's account | New manufacturer's account | Original manufacturer's account |
| EUDAMED UDI/Device registrant | Original manufacturer (manufacturer SRN) | New manufacturer (manufacturer SRN) | Original manufacturer (manufacturer SRN) |
| Conformity assessment | Original manufacturer's procedure (notified body where the class requires it) | Applicable procedure for the new manufacturer (notified body where the class requires it) | Article 16(4) notified-body certificate of the relabeler's Article 16(3) QMS |
| Who places the UDI on the device or packaging | Original manufacturer (Annex VI Part C 2.3) | New manufacturer | Original manufacturer; carrier must remain readable |
When Must a Second Trade Name Get a Second UDI-DI, and When Does It Need a New Basic UDI-DI?
Understanding the hierarchy between trade names, UDI-DIs, and Basic UDI-DIs is what prevents the usual EUDAMED grouping error.
The Trade Name to UDI-DI Relationship
MDCG 2022-7 Question 1 and MDR/IVDR Annex VI Part C Section 3.9 require a new UDI-DI whenever a change could lead to misidentification or ambiguity in traceability. The listed triggers include a change of name or trade name, device version or model, quantity in a package, sterile status, and certain critical warnings.
Issuing-entity rules (for example GS1 GTIN allocation) independently expect a distinct primary identifier when the branded trade item changes. MDCG 2026-5 then confirms the compliance point that SERP notes often stop at: two UDI-DIs for two trade names of the same device is correct, provided both identifiers are assigned by and linked to the legal manufacturer.
The Basic UDI-DI Relationship and MDCG 2022-7 Q2
The Basic UDI-DI is the primary access key in EUDAMED and in certificates, declarations of conformity, and technical documentation. It groups devices that share intended purpose, risk class, and essential design and manufacturing characteristics.
| Identifier | Pathway A example |
|---|---|
| Basic UDI-DI | One manufacturer-assigned Basic UDI-DI covering the model group |
| UDI-DI #1 | Manufacturer brand trade name; manufacturer's issuing-entity account |
| UDI-DI #2 | Distributor house-brand trade name; same manufacturer's issuing-entity account |
As clarified in MDCG 2022-7 Question 2:
- Under the Article 16(1)(a) exception, a distributor's private trade name does not justify a separate Basic UDI-DI. Add the secondary UDI-DI under the original manufacturer's existing Basic UDI-DI.
- Under Pathway B, the new manufacturer cannot reuse the original manufacturer's Basic UDI-DI. It must assign its own.
Common failure mode: Some market commentaries imply that distributors operating under an Article 16(1)(a) agreement should assign their own Basic UDI-DIs. That reverses MDCG 2022-7 Q2. Creating a second Basic UDI-DI for a manufacturer-on-label device splits the regulatory grouping without a new legal manufacturer. Review Mistake 3: Flawed Basic UDI-DI Strategy when you audit grouping. EUDAMED will not necessarily auto-reject a bad grouping; the error often surfaces later in notified-body or competent-authority review.
Who May Receive Codes from GS1, HIBCC, ICCBBA or IFA, and What May Be Delegated?
To obtain legitimate UDI-DIs in the European Union, the manufacturer obtains identification numbers from a designated issuing entity.
The Four Designated EU Issuing Entities
Commission Implementing Decision (EU) 2019/939 designated four issuing entities. Commission Implementing Decision (EU) 2024/2120 of 30 July 2024 renewed those designations from 27 June 2024 until 27 June 2029. The Commission UDI page lists them as the entities that provide manufacturers with UDIs:
- GS1 AISBL (GTINs and Global Model Numbers for Basic UDI-DI)
- Health Industry Business Communications Council (HIBCC)
- ICCBBA
- Informationsstelle für Arzneispezialitäten — IFA GmbH
Deconstructing the EU UDI Helpdesk "Delegation" Sentence
A major source of confusion is language on the European Commission UDI Helpdesk, which MDCG 2026-5 quotes:
the manufacturer may in principle delegate the practical operation of UDI assignment and application to a third party (e.g. under a contractual agreement), however the ultimate legal liability for complying with UDI obligations remains with the manufacturer
Some distributors read "practical operation" as permission to open their own GS1 or HIBCC accounts, generate GTINs under their corporate prefixes, and license those codes back to the manufacturer named on the label.
MDCG 2026-5 limits that reading. The Helpdesk sentence does not disappear, but the paper says MDR/IVDR and the Helpdesk should not be interpreted as allowing authorised representatives, distributors, or importers to assign UDIs. The manufacturer indicated on the label and in the device documentation is the only entity that may assign UDIs, receive codes from EU UDI issuing entities linked to itself, and register the device in EUDAMED. A third party may still interact with issuing entities on behalf of the manufacturer.
- What may be delegated: formatting carriers, operating printers, preparing EUDAMED submissions, or acting as an agent on the manufacturer's issuing-entity account, under contract.
- What cannot be delegated: substituting the distributor's (or AR's or importer's) own company prefix as the code-holder of record for a device whose label names someone else as manufacturer. See EUDAMED Registration Requirements for authorised-representative boundaries.
Who Registers the Device in EUDAMED, and What Must Importers and Distributors Still Verify?
Device registration is governed by MDR Article 29 and IVDR Article 26. MDCG 2026-5 is explicit: the manufacturer indicated on the label is the only entity that can register the device in EUDAMED.
| Question | Pathway A / C answer |
|---|---|
| Who submits UDI/Device data? | The legal manufacturer, via its manufacturer actor account |
| Which SRN sits on the device record? | The legal manufacturer's manufacturer SRN |
| Does a distributor register the device while remaining a distributor? | No. On Pathway B the former distributor registers as manufacturer |
| What does an importer still do? | Actor registration where required, plus verification that the manufacturer assigned a UDI and, under MDR Article 13(4), that the device is registered in accordance with Article 29 |
Actor-module validation by the relevant competent authority is a separate step from UDI/Device data entry. Do not treat notified-body surveillance as a substitute for correct manufacturer-side device registration.
EUDAMED Module Status and Legal Timelines
The EUDAMED UDI/Device module became mandatory for new devices placed on the EU market from 28 May 2026, following Commission Decision (EU) 2025/2371 of 26 November 2025. Legacy devices transitioning under MDR Article 120 / IVDR Article 110 must complete registration by 27 November 2026 on the timetable already documented on this site.
Timeline distinction: 27 November 2026 is the legacy-device EUDAMED registration date. It is not an MDCG 2026-5 grace period or effective date. MDCG 2026-5 is interpretive guidance with no transition clock in the paper. For the registration timetable, see Device Registration Deadlines.
Public EUDAMED Cannot Census Distributor-Held Codes
A 25 July 2026 public EUDAMED device-search extract contained 2,926,029 unique UDI/device search records. That figure is a scale marker and a completeness warning, not a census of private-label arrangements or of non-compliant distributor-held codes. The extract predates MDCG 2026-5. Public rows under-count the live database, and they are UDI/device search records rather than de-duplicated legal manufacturers.
Public fields useful for this question include manufacturer name and SRN, trade name, Basic UDI, primary DI, and issuing agency. They do not include the issuing-entity account holder. A trade name that differs from the manufacturer name does not prove who requested the code or who paid GS1, HIBCC, ICCBBA, or IFA.
| Public field | What it can show | What it cannot show |
|---|---|---|
| Manufacturer name / SRN | Who is declared as manufacturer on the record | Who holds the GS1/HIBCC/ICCBBA/IFA membership |
| Trade name | The branded name on the device record | Whether that brand is an Article 16(1)(a) house brand |
| Primary DI / Basic UDI | The identifiers registered | Whether the prefix was issued on a distributor account |
| Issuing agency | Which system (when populated) | Account-holder identity; the field is often blank |
Competent authorities and notified bodies discover account-holder mismatches by comparing issuing-entity membership or company-prefix records with labels and EUDAMED, not by a public-search filter. For landscape context on an older extract, see EUDAMED at a Glance. Do not reuse that article's country or manufacturer rankings here.
Economic Operator Verification Obligations
Before making a device available, distributors must verify that, where applicable, a UDI has been assigned by the manufacturer — MDR Article 14(2)(d) (not 14(2)(c), which is the importer's Article 13(3) particulars on imported devices). IVDR Article 14(2)(d) is the analogue. Importers have the parallel UDI check under MDR Article 13(2)(d) / IVDR Article 13(2)(d).
If a distributor knows the UDI-DI on the packaging was generated from its own corporate account while another entity remains the manufacturer on the label, it is making available a device that does not match the MDCG 2026-5 reading of assignment and is also failing that Article 14 verification.
How Should Manufacturers Correct UDI-DIs Already Issued in a Distributor's Name?
MDCG 2026-5 does not publish a remediation clock, an issuing-entity transfer SOP, or an enforcement case. Treat the following as an operational sequence, not a legal deadline.
- Portfolio identification. Cross-reference private-label and house-brand agreements against GS1/HIBCC/ICCBBA/IFA company-prefix records. Flag every SKU whose UDI-DI prefix is not the legal manufacturer's.
- Legal pathway validation. Decide Pathway A, B, or C for each arrangement. Do not force every own-brand deal into a new legal manufacturer. Amend Pathway A contracts so Article 16(1)(a) language, label identity, and UDI-account ownership are explicit. See Regulatory Identity: Who Is Your Distributor?.
- Manufacturer code allocation. The legal manufacturer allocates replacement UDI-DIs from its own issuing-entity subscription for each private-label trade name that will remain manufacturer-on-label.
- Artwork and IFU cut-over. Update packaging, sterile-barrier labels where the carrier changes, and IFU references. Do not reprint until the manufacturer's codes exist.
- EUDAMED alignment. Register the new UDI-DIs under the existing Basic UDI-DI (Pathway A) or under the new manufacturer's Basic UDI-DI (Pathway B). If distributor-held codes were uploaded in error, coordinate correction with EUDAMED support and, where needed, the competent authority; do not assume a silent overwrite.
- Supply-chain mapping. Notify hospital purchasing networks, group purchasing organisations, and wholesale distributors of the GTIN/UPN transition so automated catalogues do not reject orders.
What Label, Artwork, Contract and Issuing-Entity Changes Follow a Number Change?
| Functional area | Typical changes | Basis |
|---|---|---|
| Physical labelling | 1D/2D carriers (GS1 DataMatrix or HIBC), human-readable interpretation, packaging hierarchy | MDR Annex I Chapter III (Section 23); Annex VI Part C |
| Instructions for use | Model numbers, catalogue codes, and trade names aligned to the new UDI-DI table | MDR Annex I Section 23.4 |
| Technical documentation | Device description including Basic UDI-DI (Annex II Section 1.1(b)) and consistent UDI-DI lists in specifications | MDR Annex II Section 1.1 — not Section 1.2, which is previous and similar generations |
| Declaration of conformity | List the relevant UDI-DI(s) with the Basic UDI-DI | MDR Article 19; Annex IV |
| Distribution agreements | UDI ownership, delegation limits, and notification of number changes | MDR Article 16(1)(a) where that path applies |
| EUDAMED | New UDI-DI attributes under the manufacturer's SRN | MDR Article 29; Commission Decision (EU) 2025/2371 |
| Commercial IT | Master data, ERP item masters, GDSN pools, hospital EDI | Issuing-entity and customer-catalogue rules, not MDR fee schedules |
What Does This Cost Beyond an Issuing-Entity Account Fee?
MDCG 2026-5 does not publish fees. Do not treat an issuing-entity invoice as the project cost, and do not treat the figures below as guaranteed euro amounts — they are cost categories, not a quote.
| Cost category | What sits in it | Source basis |
|---|---|---|
| Issuing-entity fees | Company-prefix membership, extra GTIN/UPN allocations, Basic UDI-DI / GMN tools | Provider prices from GS1 Member Organisations, HIBCC, ICCBBA, or IFA — not government statutory fees |
| Artwork and pre-press | Graphic changes, plates, IFU typesetting, barcode verification (for example ISO/IEC 15415) | Provider prices |
| Inventory | Scrap or rework of pre-printed packaging that carries a distributor-held code; sterile re-labelling risk | Internal / MedDeviceGuide analysis — no official schedule |
| Regulatory and legal labour | Article 16(1)(a) addenda, technical-documentation edits, notified-body questions, EUDAMED submission labour | Internal or consultant labour |
| Downstream remapping | Hospital EDI, national procurement catalogues, distributor portals, overlapping old and new codes during cut-over | Internal / customer-system labour; see The Deadline Has Passed — Now the Real Work Begins |
How Is This Different from FDA GUDID Private-Label / Labeler Rules?
Do not import United States GUDID "labeler" logic into MDR.
| Dimension | US FDA (21 CFR 801 / 830) | EU MDR / IVDR |
|---|---|---|
| Core regulated actor for UDI | "Labeler" (21 CFR 801.3) | Manufacturer (MDR Article 2(30)) |
| Private-label distributor | Often the labeler if that person causes the commercial label to be applied or replaced | Remains a distributor on Pathway A; becomes manufacturer on Pathway B |
| Who assigns the UDI-DI | The labeler | The legal manufacturer (MDCG 2026-5; Annex VI Part C 2.2) |
| Database key | Primary DI in GUDID | Basic UDI-DI grouping plus UDI-DI |
| Actor identifier | Establishment registration / DUNS as used in GUDID | EUDAMED actor SRN |
Under 21 CFR 801.3, a labeler is a person who causes a label to be applied, or who causes the label to be replaced or modified, with the intent that the device will be commercially distributed without a later label replacement or modification. Adding only the name and contact information of a person who distributes the device, without other label changes, is not a modification that makes that person a labeler.
A US private-label firm that does cause the commercial label to be applied or replaced is generally the GUDID labeler and assigns its own UDI-DI. That US result does not decide MDR Article 16. See The GUDID Data-Quality Checklist for a Contract Portfolio for the US regime, and EU MDR: Article 27 and the Basic UDI-DI for a cross-jurisdiction identifier comparison.
Under EU MDR, there is no "labeler" operator. If a private-label distributor assigns the UDI-DI in its own name while remaining a distributor, that is the practice MDCG 2026-5 rejects. If it assigns UDI because it has become the manufacturer under Article 16(1), that is Pathway B.
MDCG 2026-5 30/60/90-Day Readiness Plan
Use this as an operational cleanup sequence. The position paper does not require a 90-day programme.
Days 1–30: Audit and classification
- List private-label, house-brand, and localised trade-name agreements in the EU.
- Collect issuing-entity company-prefix certificates for every active UDI-DI. Flag prefixes owned by a distributor, AR, or importer.
- Classify each SKU as Pathway A, B, or C. Confirm who is named as manufacturer on current labels.
Days 31–60: Contracts and identifier allocation
- Execute Article 16(1)(a) addenda where Pathway A is the intended structure: manufacturer on the label, manufacturer responsible for manufacturer requirements, manufacturer holds issuing-entity accounts and EUDAMED device records.
- Allocate replacement UDI-DIs from the legal manufacturer's account for Pathway A brands.
- Draft artwork only after those codes exist. Update technical documentation (Annex II Section 1.1) and labelling specifications — not a US-style "design history file" as the MDR artefact.
Days 61–90: Packaging cut-over and EUDAMED
- Implement artwork cut-over with documented inventory batch cut-offs.
- Submit or update UDI-DI records under the correct Basic UDI-DI and manufacturer SRN.
- Issue old-to-new identifier mapping tables to distributor commercial teams and hospital procurement.
| Window | Outcome |
|---|---|
| Days 1–30 | Pathway map and prefix exceptions, not yet a number change |
| Days 31–60 | Contracts and manufacturer-held codes; artwork in draft |
| Days 61–90 | Physical cut-over, EUDAMED alignment, customer catalogue notices |
Frequently Asked Questions
Has MDCG 2026-5 changed MDR or IVDR text, or is it interpretive guidance?
MDCG 2026-5 has not changed MDR or IVDR text. It is an interpretive position paper. It is not legally binding; only the CJEU can give binding interpretations. It is still the document Member State authorities are expected to use for consistent enforcement of existing UDI rules.
Can a distributor obtain a UDI-DI in its own name if an Article 16(1)(a) agreement keeps the manufacturer on the label?
No. That is the specific practice MDCG 2026-5 addresses. Extra UDI-DIs for extra trade names must be allocated by and linked exclusively to the legal manufacturer.
If we sell the same device under two brands, do we need two UDI-DIs, two Basic UDI-DIs, or both?
Under Pathway A: two UDI-DIs, one Basic UDI-DI. Under Pathway B: a new Basic UDI-DI and new UDI-DIs for the new manufacturer. Annex VI Part C 3.9 is why the second trade name needs its own UDI-DI; MDCG 2022-7 Q2 is why that does not, on Pathway A, create a second Basic UDI-DI.
Can we contract the distributor or a service provider to apply for codes and enter EUDAMED data?
Yes, as an agent of the manufacturer, not as code-holder of record. Practical assignment, carrier application, and EUDAMED data entry may be delegated under contract. The issuing-entity account and the EUDAMED manufacturer SRN must still be the manufacturer's, and legal liability stays with the manufacturer.
If the distributor becomes the manufacturer under Article 16(1), who holds the Basic UDI-DI and the SRN?
The new manufacturer. MDCG 2022-7 Q2: new Basic UDI-DI, manufacturer registration and SRN, appropriate conformity assessment, and UDI/device registration.
Do Article 16(2) translation or repackaging activities let the importer assign a new UDI-DI?
No. Original manufacturer UDI-DI and Basic UDI-DI remain. Preserve carrier readability and meet Article 16(3)–(4).
Can public EUDAMED search show whether a UDI-DI was requested on a distributor's issuing-entity account?
No. Public records can show manufacturer, SRN, trade name, and identifiers. They do not display the corporate account holder at GS1, HIBCC, ICCBBA, or IFA. Audit membership certificates.
How Pure Global Supports EU MDR/IVDR and UDI Compliance
Navigating private-label distribution structures, EUDAMED data synchronization, and MDCG position papers requires coordinated regulatory and operational execution. Pure Global provides independent regulatory consulting, QMS alignment, and transition management for medical device and IVD manufacturers entering and expanding across the European Union.
Our regulatory teams assist manufacturers with:
- Auditing global distribution portfolios against MDCG 2026-5 and MDR Article 16 requirements.
- Structuring compliant EU MDR consulting and EU IVDR consulting frameworks.
- Establishing compliant Basic UDI-DI grouping strategies and managing bulk EUDAMED UDI/Device submissions.
- Reviewing and redrafting regulatory clauses in distributor and importer agreements.
To assess your UDI allocation architecture and ensure your European product portfolio meets the latest MDCG standards, contact Pure Global.
Disclaimer: Pure Global provides independent regulatory and compliance consulting services. Pure Global is not a Notified Body, European Competent Authority, or designated UDI Issuing Entity, and does not issue CE certificates or statutory UDI company prefixes.
Sources
- MDCG 2026-5 Position Paper: UDI assignment between manufacturers and distributors (PDF) — Medical Device Coordination Group (July 2026).
- MDCG 2022-7 Questions and Answers on the Unique Device Identification System (PDF) — Medical Device Coordination Group (Question 1 on Annex VI Part C 3.9; Question 2 on Article 16(1) / 16(1)(a)).
- Regulation (EU) 2017/745 on Medical Devices (MDR) Consolidated Text — Articles 10, 13, 14, 16, 19, 27, 29, Annex I Section 23, Annex II Section 1.1, and Annex VI Part C.
- Regulation (EU) 2017/746 on In Vitro Diagnostic Medical Devices (IVDR) — Articles 10, 13, 14, 16, 24, 26, and Annex VI Part C.
- EU UDI Helpdesk: UDI Assignment Obligations — European Commission Directorate-General for Health and Food Safety (DG SANTE).
- European Commission Unique Device Identifier (UDI) Overview and Issuing Entities — European Commission DG SANTE.
- Commission Implementing Decision (EU) 2019/939 — designation of GS1 AISBL, HIBCC, ICCBBA, and IFA GmbH.
- Commission Implementing Decision (EU) 2024/2120 — Official Journal; designations renewed until 27 June 2029.
- EUDAMED UDI/Device Registration Module Overview — European Commission; mandatory use from 28 May 2026 under Commission Decision (EU) 2025/2371.
- MDCG Endorsed Documents and Other Guidance Index — lists MDCG 2026-5 under July 2026.
- 21 CFR 801.3 — Definitions (labeler) — US contrast only.
- EUDAMate: Who Can Assign a UDI-DI? Manufacturer vs. Distributor — commercial explainer used as SERP baseline, not official (retrieved 25 August 2026).